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General background 
1. Multiple myeloma 
Multiple myeloma (MM) is a progressive clonal B-cell disorder characterized 
by proliferation and accumulation of malignant plasma cells in the bone marrow 
and, less frequently, at extra-medullary sites (Figure 1) [1,2]. This malignant cells 
are phenotypically similar to long-lived plasma cells, including a strong 
dependence on the bone marrow microenvironment for survival and growth [3]. 
They typically secrete a single electrophoretically homogenous immunoglobulin 
(Ig) product, known as the monoclonal (M) protein (Figure 2), whereas the normal 
Ig levels are decreased [4,5]. In most of the cases the serum M-protein is of the 
IgG class, the IgA class is frequently involve as well, whereas IgM, IgE and IgD 
are rarely found. 
 
Figure 1. Smear of normal bone marrow (A) and in a patient affected by MM (B), with 
extensive infiltration by malignant plasma cells. 
A 
 
B 
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Figure 2. Electrophoretic pattern of a normal person (blue) and of a MM patient (violet). 
 
2. Epidemiology and etiology of multiple myeloma 
MM is a devastating, incurable malignancy which constitutes 1% of al cancers. 
It represents the second most frequent malignancy of the blood after lymphomas, 
accounting for 10% of all haematological malignancies [6]. MM is a disease of the 
elderly, the median age at onset is approximately 70 years. Only 15% of patients 
are aged less than 60 years, and rarely - less than 2-3% of patients - are 
diagnosed before the age of 40 [7]. On a worldwide scale, it is estimated that 
about 86 000 incident cases occur annually, accounting for about 0.8% of all new 
cancer cases. About 63 000 subjects are reported to die from the disease each 
year (~1% of all cancer deaths) [8]. MM incidence rate is significantly affected by 
race and gender. It is more common in the black race, followed by Maoris, 
Hawaiians, Israeli Jews, northern Europeans, US and Canadian whites, 
respectively [5,9,10]. The lowest rates occur in the Middle East, Japan, and China 
[9]. MM is also significantly higher in males than females among both, black and 
white population. 
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The cause of MM is still uncertain. The strongest environmental factor associated 
with an increased risk of developing MM is ionizing radiation [11]. However further 
studies on nuclear bomb survivors in Japan found no such relation [12]. Other 
factors associated with increased risk of MM are smoking, exposure to metals, 
agricultural chemicals, benzene and other petroleum products [11,13]. A direct 
genetic linkage to the etiology of MM has not yet been established. However, the 
remarkable difference in the incidence rate between different races, and the 
preservation of these incidence patterns regardless migration, suggest that 
susceptibility to MM may be determined by hereditary and genetic rather than 
environmental factors. 
 
3. Clinical features of multiple myeloma 
The clinical signs and symptoms in MM may vary greatly. Skeletal destructions 
or osteolytic lesions (Figure 3) are a characteristic feature of MM, being found in 
70% of all cases. The lower back, ribs, and spine are the most commonly affected 
areas. The lesions are due to an unbalanced process between the cells 
reabsorbing bone (osteoclasts) and the cells producing bone (osteoblasts). The 
skeletal lesions and their accompanying hypercalcemia give rise to asthenia, 
cachexia, bone pain, fractures, compression of the spinal cord, and renal 
insufficiency, and are major causes of morbidity [3]. As the malignant cells grow 
they displace red blood cells and excrete inhibitory factors that prevent 
erythropoiesis, leading to anemia. MM patients are also more susceptible to 
bacterial infections due to deficiencies in both the humoral and cellular immunity. 
Renal failure is one of the most serious adverse complications of MM, and is 
caused by accumulation of Ig as well as deposition of calcium in the kidneys, 
leading to obstruction and inflammation. Neurological symptoms are most 
commonly related to the effect of the tumor mass, e.g. compression of the spinal 
cord or the nerves, but can also be due to hypercalcemia, hyperviscosity, or 
depositions of amyloids [3]. 
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Figure 3. Typical bone lesion induced by MM: the skull !-ray shows rounded "punched 
out lesion” (arrowhead)  
 
3.1. Diagnosis and course of the disease  
The diagnosis of MM is based on the presence of M-protein, bone marrow 
plasmacytosis and evidence of organ or tissue-related damage (i.e. bone lesions, 
kidney failure) to the body as a result of myeloma, and not other cause. Recently, 
the International Myeloma Working Group agreed on new consensus criteria for 
the classification of multiple myeloma and other gammopathy [4]. In this 
classification, the concept of end-organ damage was introduced to distinguish 
between monoclonal gammopathy of undetermined significance (MGUS), 
asymptomatic myeloma (smouldering MM -SMM) and symptomatic myeloma. 
MGUS and SMM are asymptomatic, pre-malignant disorders, characterized by 
clonal expansion of plasma cells within the bone marrow, which is responsible for 
the presence of an M-protein in the serum, but with no evidence of end-organ 
impairment [4,14]. Patients with MGUS and SMM are often diagnosed by chance, 
as M-proteins are frequently identified during investigation of unrelated symptoms 
or during health screening. These patients are associated with an increased risk of 
developing and require lifelong observation in order to detect signs of 
transformation. The purpose of monitoring is to try to identify transformation to a 
malignant disorder at an early stage, when there is no significant irreversible lytic 
bone disease, renal failure or other disabling symptoms and at a stage when the 
patient is fit enough to benefit from increasingly effective treatments.  
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MGUS or SMM patients are not treated unless progression occurs. However, 
SMM needs to be differentiated from MGUS in the clinical setting, as its rate of 
transformation is markedly higher (Figure 4; [15]). The rate of progression of 
MGUS is ~1% per year vs 10% per year for SMM. By virtue of this different 
probability of progression between SMM and MGUS, SMM patients should be 
managed differently in  terms of frequency of follow-up [14,16]. 
 
 
Figure 4. Probability of progression to active MM in patients with SMM or MGUS (vertical 
bar represents 95% confidence intervals). 
 
At present no methods are available to distinguish those who will later develop 
MM from those who do not. Until recently it was not clear whether all MM were 
preceded by an MGUS phase. A study by Landgren et al., and another by Weiss 
et al., offered important clues about MGUS and its relationship to MM [17,18]. 
These two studies indicated that virtually all MM cases were preceded by an 
MGUS phase. This is a key finding that helps to fill a gap in our understanding of 
myelomagenesis. However, the events that trigger progression of MGUS to MM is 
are currently still unknown. These with other studies led to the generation of a 
disease model based on the multistep progression of normal to MGUS through to 
myelomatous plasma cells. In this model the initiating event is thought to be an 
immortalisation episode in plasma cell, which initiates the formation of a clone. It 
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has been suggested that such clone may remain quiescent and non-accumulating 
without producing end organ damage (MGUS/SMM stage). If transformation 
occurs, plasma cells accumulate within the bone marrow leading to organ and 
tissue impairment. This disease usually enters a quiescent phase of variable 
duration, followed by a late stage of drug resistance with resistance to apoptosis 
and independence from the bone marrow microenvironment. 
The multi-step model of the molecular pathogenesis of MM as proposed is 
summarized in Figure 5 [3,19].  
 
Figure 5. Development and molecular pathogenesis of MM. (A) Developing MM occurs 
either from a MGUS, or arises directly from a normal germinal-centre B cell. Plasma cells 
accumulate within the bone marrow (intramedullary MM), leading to manifestation of 
clinical features. Thus, intramedullary myeloma is associated with severe secondary 
features (lytic bone lesions, anaemia, immunodeficiency and renal impairment) and, in 
some patients with tumours occurring in extramedullary sites (blood, pleural fluid and 
skin). With progression to malignant myeloma, complex changes occur in the bone 
marrow microenvironment, i.e. induction of angiogenesis, suppression of cell-mediated 
immunity, and development of paracrine signalling loops (involving cytokines such as IL-
6, IGF-1, and VEGF). These changes lead to interactions of myeloma cells, bone marrow 
stromal cells, and microvessels which, taken together contribute to persistence of the 
tumour and its resistance to drugs. (B) Oncogenic events occur in MGUS and throughout 
the course of MM, such as karyotypic instability; primary and secondary immunoglobulin 
(Ig) translocations, chromosome deletion, and gene mutations. 
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4. Genetic abnormalities in multiple myeloma 
The acquisition of recurrent chromosomal abnormalities is an early event in 
MM development, as many of the genetic changes identified in the PC of MM 
patients have also been found in MGUS and SMM. Although, the mechanisms 
responsible for the acquisition of these changes is not well understood, current 
evidence suggests that in many cases an abnormal response to antigenic 
stimulation may be a key factor [20-22]. 
Conventional cytogenetics and fluorescent in-situ hybridization (FISH) have shown 
that numeric abnormalities occur in the genes of MM cells in both a non-
hyperdiploid and a hyperdiploid pattern (Figure 6; [23]). Non-hyperdiploid 
abnormalities (black triangle in Figure 8) usually includes one of the seven 
recurrent IgH translocations as an early event, hyperdiploid (white triangle in figure 
6) is associated with multiple trisomies. Monosomy/deletion of chromosome 13 
("13; grey triangle in figure ) has also been suggested to be an early abnormality 
shared by MGUS and MM tumours. IgH translocations, hyperdiploid, and "13 are 
all early and partially overlapping events; however, the relative timing of their 
occurrence is not yet completely understood. Secondary chromosomal 
rearrangements and other abnormalities, implicated in disease progression, can 
occur at any time during tumourigenesis. These includes MYC rearrangement, 
activation of N or K-RAS mutations, FGFR3 mutations, inactivation or mutation of 
TP53, RB1 and PTEN; and inactivation of cyclin-dependent kinase inhibitors 
CDKN2A and CDKN2C. 
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Figure 6. Disease stages and timing of oncogenic events. 
 
Translocations involving the Ig heavy chain locus (14q32) are present in 
approximately 75% of the newly diagnosed.  The translocation partners of 14q32 
are quite heterogeneous with 4p16.3, 11q13 and 16q23 being most frequently 
involved. The t(4;14)(p16.3;q32) and t(14;16)(q32;q23) are associated with poor 
prognosis after high-dose chemotherapy [24].  
The t(4;14)(p16.3;q32) is present in approximately 20% of the patients. The 
translocation results in expression of multiple myeloma SET domain (mmset) 
and/or fibroblast growth factor receptor 3 (FGFR3), which promotes myeloma cell 
proliferation and prevents apoptosis [25]. The t(14;16)(q32;q23) is present in 10% 
of the patients and results in expression of c-maf [26]. Other chromosomal 
abnormalities associated with poor prognosis are 17p13 deletion (p53), and 
translocations involving c-myc (8q24) [27,28]. 
The t(11:14)(q13;q32) and hyperdiploid karyotype are chromosomal abnormalities 
associated with a favorable prognosis. The t(11:14)(q13;q32) is detected in 20% 
of the patients and results in expression of cyclin D1 [29,30]. Hyperdiploid 
karyotype is observed in 40-50% of the patients with multiple myeloma. The 
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majority of these patients have a chromosome pattern, which consists of the 
combination trisomies of chromosomes 5, 7, 9, 11, 15, 19 and 21, and low 
prevalence of chromosome 13 deletions. Several studies have shown that 
hyperdiploid-myeloma patients have a better prognosis than non-hyperdiploid-
myeloma patients [31,32]. 
 
5. Prognostic factors associated with tumor burden 
The tumor burden can be assessed by means of the Durie and Salmon 
staging system, which was specifically obtained from mathematical models for 
evaluation of tumor mass. Multiple myeloma was divided in three tumor burden 
groups, which correlated with survival [33]. Recently, a new staging system has 
been proposed. The International Staging System (ISS) was obtained from 
statistical analysis of potential prognostic factors in a large international data set of 
symptomatic myeloma patients. 
The individual most powerful prognostic marker is the serum β2-microglobulin 
level, which is a single variable that measures a combination of indices: cell 
proliferation, cell mass, and renal function. Genetic factors are also important 
prognostic markers. Favourable prognostic marker include a β2-microglobulin 
level < 2.5 mg/L, absence of deletion or monosomy of chromosome 13, and 
t(11;14). Prognostic markers related to an adverse outcome include increase in 
plasma cell labelling index, increased levels of serum β2-microglobulin, and 
circulating myeloma cells. Complete deletion of chromosome 13 or its long arm, 
t(4,14) as well as increased density of bone marrow microvessels are also 
adverse prognostic factors [1]. 
Based on the results of two widely available laboratory tests, serum β2-
microglobulin and albumin concentration, multiple myeloma is divided in three 
stages in which the median survival ranging from 29 to 62 months (Table 1) [34] 
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Table 1. International Staging System for multiple myeloma [34] 
 
Stage  Criteria           Survival (months) 
 
I Serum β2-microglobulin < 3.5 mg/l     62 
and serum albumin ≥ 35 g/l 
 
II Serum β2-microglobulin < 3.5 mg/l     45 
and serum albumin < 35 g/l  
or  serum β2-microglobulin > 3.5 to < 5.5 mg/l 
 
III Serum β2-microglobulin ≥ 5.5 mg/l     29 
 
 
6. Treatment of multiple myeloma 
To date MM remains an incurable disease. However, treatment improves the 
clinical situation in 75% of patients and multiple periods of remission and relapse 
can occur. In particular, high-dose chemotherapy supported by haematopoietic 
stem cell transplantation (HSCT), and the latest integration of several novel agents 
(Figure 7; [2]), into each step of therapeutics have substantially improved the 
outcome of patients with MM [35]. 
MM treatment can be divided into three phases: induction, consolidation and 
maintenance. Currently the treatment of choice for symptomatic MM is high-dose 
chemotherapy with haematopoietic stem cell transplantation (HSCT). Autologous 
HSCT uses the patient's own stem cells, whereas allogeneic/syngeneic HSCT 
employs MHC (i.e. HLA) identical or twin donor bone marrow. If HSCT is not an 
option (depending on the individual situation of the patient i.e., age, state of the 
disease, physical fitness) a simple induction regime with conventional 
chemotherapy, single agent treatment (e.g., dexamethasone) or new treatments 
(thalidomide, bortezomib) possibly in combination with other drugs are applied. 
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Figure 7. Timeline of treatment evolution in MM. 
 
6.1. Conventional agents 
The first successful myeloma treatment - a combination of melphalan and 
prednisone - was introduced in the late 1960s, and was further improved by high-
dose drug regimens with autologous stem-cell transplantation in the 1980s. 
Median survival after conventional treatments was only 3 to 4 years, but high-dose 
treatment followed by autologous stem-cell transplantation extended median 
survival to 5 to 7 years [36]. This was the treatment for MM until the 1980s when 
vincristine, doxorubicin, and dexamehasone (VAD) followed by autologous 
transplant became the standard of care for eligible patients [37,38].  
Most newly diagnosed MM patients <65 years of age (or older if fit) are candidates 
for autologous transplant. Therefore initial therapy must avoid agents with 
cumulative myelosuppression in order to permit collection of an adequate number 
of stem cells. Common pre-autologous transplant induction regimens have 
included the VAD regimen. This produces partial remission (PR) in about 50% of 
patients and complete remissions (CR) (no evidence of monoclonal protein and 
<5% marrow plasma cells) in 5 to 10% of patients 
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6.2. Novel agents 
The new era of treatment for multiple myeloma was not initiated until the late 
1990s with the introduction of thalidomide, its analogue lenalidomide, and 
bortezomib. 
 
6.2.1. Thalidomide 
In 1999, thalidomide was introduced as a new therapeutic agent in the 
treatment of multiple myeloma. The rationale for the use of thalidomide was based 
on studies showing increased bone marrow microvascularity in multiple myeloma 
[39] and the observation that thalidomide had anti-angiogenic activity in animal 
models [40]. The first clinical trial with thalidomide was conducted by Singhal et al. 
[41] in patients with relapsed or refractory multiple myeloma. The response rate 
was 30%. The event-free and overall survivals at 2 years were 20% and 48%, 
respectively. When Thalidomide showed promising activity in relapsed myeloma, it 
was quickly combined with Dexamethasone (TD regimen) in an attempt to develop 
an oral alternative to the cumbersome VAD regimen. Dexamethasone and the 
other steroids are useful in myeloma treatment because they can stop white blood 
cells from travelling to areas where cancerous myeloma cells are causing 
damage. This decreases the amount of swelling or inflammation in those areas 
and relieves associated pain and pressure. Several studies have confirmed the 
efficacy of thalidomide alone and in combination with dexamethasone or 
chemotherapy for the treatment of myeloma patients with relapsed and refractory 
disease [42-45]. 
Subsequently, thalidomide was extensively investigated in newly diagnosed 
patients. Three studies reported on the combination TD [46-48]. Objective 
responses were observed in 63% to 72% of patients, with a complete response 
rate of approximately 10%. Even there are no randomized studies comparing TD, 
and VAD like regiments, a matched case-control study by Cavo et al., [49] 
reported a significantly higher response rate with TD as compared to VAD (76% 
vs. 52%); the complete response rate was 10% and 8%, respectively. Overall, 
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these studies indicate that the TD is a relatively safe and effective induction 
regimen that does not impair stem cell collection. Thalidomide is being 
investigated also in the maintenance setting for its effect on the duration of 
response after high-dose chemotherapy and HSCT [50]. In this study –  
– IFM 99 2 – patients were randomly assigned to no maintenance treatment, 
maintenance with pamidronate alone or maintenance with thalidomide and 
pamidronate. Thalidomide increased the overall survival compared with the other 
two groups. The 4-years probability of survival was 77% in the no maintenance 
group, 74% in the pamidronate group and 87% in the thalidomide and 
pamidronate group. 
Disadvantages of thalidomide include a variety of side effects such as deep vein 
thrombosis, constipation, peripheral neuropathy, and fatigue, which often restrict 
dose and treatment duration thus reducing drug effectiveness [51]. 
 
6.2.2. Lenalidomide 
Lenalidomide is an immunomodulatory drug, analogue of thalidomide, that has 
demonstrated significantly more potent preclinical activity compared with 
thalidomide, and without sedative and neurotoxic adverse effects [52]. A 
multicenter phase II study [53] reported a response rate of 24%. Approximately, 
one third of the patients who did not respond to lenalidomide alone, had an 
additional responses when dexamethasone was added to the regimen. Two other 
randomized phase III studies have compared lenalidomide and dexamethasone to 
dexamethasone alone in patients with relapsed or refractory disease. Interim 
analyses of both studies showed a higher response rate and improved time to 
progression in favour of the lenalidomide and dexamethasone group [54]. 
Recently, Rajkumar et al [55] investigated lenalidomide in combination with 
dexamethasone in newly diagnosed multiple myeloma. The response rate was 
91% with a (near) complete response rate of 38%, and an adequate number of 
stem cell was obtained in all patients. 
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6.2.3. Bortezomib 
Bortezomib is a novel proteasome inhibitor, which is highly active in patients 
with multiple myeloma. The proteasome-ubiquitin pathway is a ubiquitous and 
essential intracellular system that degrades many labile proteins regulating cell 
cycle, apoptosis, transcription, cell adhesion, angiogenesis, and antigen 
presentation [56,57]. Bortezomib, is a small molecule that is a potent and selective 
inhibitor of the 26S proteasome which is the primary component of the protein 
degradation pathway of the cell (Figure 8; [57,58]). Given the broad array of 
substrates, the 26S proteasome has been shown to be involved in cell cycle 
control, cell differentiation, transcription, DNA repair, and immune response, [59-
61]. The antimyeloma mechanism of bortezomib is still subject of intense study. 
 
 
 
 
 
 
 
 
 
Figure 8. (A) Structure and function of proteasomes; (B) cross-sectional view of 26S 
proteasome complex; (C) process of degradation of ubiquitinated proteins by proteasome 
complex; and (D) bortezomib/velcade blocks the proteasomal protein degradation 
resulting in accumulation of cytotoxic proteins. 
 
Bortezomib is currently believed to exert its effects through multiple pathways that 
target both the tumor cell and its microenvironment [62]. A phase II study in 
patients with relapsed or refractory multiple myeloma treated with bortezomib 
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demonstrated a response rate of 35% [63]. The median overall survival was 16 
months, with a median duration of response of 12 months. A smaller, randomized 
study confirmed the activity of bortezomib [64]. In both studies some responses 
occurred after addition of dexamethasone in patients with no or a suboptimal 
response to bortezomib alone. Chromosome 13 deletion and elevated β2-
microglobulin, generally considered as poor prognostic factors were not predictive 
of poor outcome in patients treated with bortezomib [65]. A subsequent 
international, multicenter phase III study in 669 patients, who had a relapse prior 
therapies were randomized to receive bortezomib or high-dose dexamethasone 
[66]. Bortezomib demonstrated to be superior to high-dose dexamethasone in 
terms of response rate (38% vs 18%), time to progression (6.2 months vs 3.5 
months) and 1-year survival (80% vs 66%). 
Based on preclinical findings of synergistic anti-myeloma activity with other 
agents, bortezomib-based combination regimens are under clinical investigation. 
Preliminary data from studies of bortezomib alone [67] or in combination with 
dexamethasone [64], liposomal-doxorubicin [68], melphalan and prednisone [69-
70], TD [71] or cyclophosphamide and prednisone [72] indicate encouraging 
activity with manageable toxicities in advanced and newly diagnosed myeloma 
patients. Several studies have also assessed bortezomib-based regimens as pre-
transplantation induction treatment. Bortezomib and dexamethasone [73] or 
bortezomib, adriamycin and dexamethasone [74] showed to be promising 
regimens with high complete response rates (25%) and no stem cell toxicity. 
 
6.2.3.1. Bortezomib resistance 
Although bortezomib revolutionized treatment of MM, prolonging survival in 
relapsed myeloma as well as newly diagnosed disease, resistance to therapy 
develops inevitably. Furthermore, nearly a third of the patients with multiple 
myeloma never respond to treatment with bortezomib. There are several ways to 
escape the effects of proteasome inhibition by malignant cells (Figure 9, [62]). 
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Figure 9. Mechanisms of resistance and susceptibility to proteasome inhibition 
 
6.2.3.1.1. Cell intrinsic resistance 
Drug can be effluxed from cells by transporters expressed on the external cell 
membrane after up-regulation of efflux transporters like glicoprotein-P (P-gp). 
Once inside cell, alterations in binding site for bortezomib in the proteasome 
complex can prevent drug to bind to it. As a third resistance mechanism we could 
point the increasing efficiency of alternate mechanisms of protein degradation (the 
aggresome pathway). Modulation of cell signaling pathways that are affected by 
proteasome inhibition, like DNA repair pathway, may be another mechanism of 
resistance. 
P-gp - The mechanism of resistance to bortezomib is multifactorial and while little 
is known about the interaction of bortezomib with P-gp, there are indications that 
overexpression of this pump may contribute to resistance to this agent. Rumpold 
et al .[75] showed that knockdown of P-gp resensitises P-gp-expressing cells to 
proteasome inhibitors. 
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Proteasome β5 unit - The activity of Bortezomib is directed mainly against the β5 
unit of the proteasome. It has been reported that some mutations in this catalytic 
unit may impair binding of the drug and thus decrease proteasome inhibition and 
consequently bortezomib efficacy [76]. In addition, significant up-regulation of the 
PSMB5 subunit following exposure to bortezomib has been noted. 
Aggresome pathway - Recent studies have revealed an alternative system to the 
proteasome for degradation of polyubiquitinated misfolded/unfolded proteins, 
termed the aggresome [77-78]. The aggresome pathway therefore likely provides 
a novel system for delivery of aggregated proteins from cytoplasm to lysosomes 
for degradation [79]. In view of this consideration, aggresome pathway potentially 
may compensate for proteasome inhibition and contribute to drug resistance. It 
has been hypothesized that inhibition of both proteasomal and aggresomal protein 
degradation systems could induce accumulation of polyubiquitinated proteins and 
significant cell stress, followed by activation of apoptotic cascades [79]. 
Heat shock protein Hsp27 – Upregulation of the heat shock protein Hsp27 confers 
resistance to bortezomib-induced cell death through a mechanism still undefined. 
Recently in a study by Chauhan et al., [80] blocking Hsp27 using an antisense to 
Hsp27 (AS-Hsp27) restores sensitivity to PS-341 in PS-341-resistant DHL4 
lymphoma cells. These findings provide the first evidence of potential mechanisms 
of PS-341 resistance and suggest a therapeutic advantage of using an AS-Hsp27 
to overcome PS-341 resistance. 
NFkB pathways - Activation of the non-canonical NF-kB pathway has been 
recognized in patients with multiple myeloma, and attributed to interactions of the 
myeloma cell with the bone marrow microenvironment [81]. TRAF3 is a 
recognized regulator of the non-canonical NF-kB pathway and bortezomib has 
found to have a remarkable activity in patients with inactivation of TRAF3. This 
finding suggests that one of its most important mechanisms of action in MM is the 
inhibition of the non-canonical NF-kB. pathway. Therefore, it is possible that the 
specific targeting of the direct NF-kB regulators NIK and IKKα may be particularly 
effective in MM treatment, a finding that could allow tailoring the use of this class 
of drugs in the future [81]. 
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6.2.3.1.2. Host-mediated resistance 
Interactions of MM cells with the bone marrow stromal cells (BMSCs) 
microenvironment play a critical role in the development of drug resistance. The 
crucial role in this mechanism, play cytokines and/or adhesion molecules. The 
most important cytokine in MM biology is interleukin-6 (IL-6). Under normal 
conditions, IL-6 drives B-cell differentiation, but in MM it causes proliferation, and 
inhibits apoptosis of myeloma cells. Nuclear factor-κB (NF-κB), a transcription 
factor member of the Rel family, is constitutively activated in MM and its activation 
in both MM and BMSCs mediates further IL-6 secretion, resulting in increased MM 
and BMSCs interaction [79]. IL-6 may promote resistance to bortezomib through 
different mechanisms [82]: 
• Prevention of apoptosis via the PI3K-AKT pathway; 
• Impaired immune functions by blocking differentiation of monocytes to 
dendritic cells; 
• Induction of VEGF - vascular endothelial growth factor - secretion, which 
promotes angiogenesis, stimulates growth and migration of MM cells; 
• Promoting cell proliferation via the RAS-MAPK pathway. 
 
6.2.3.2. Overcoming bortezomib resistance: Emerging therapies 
New therapies such as heat shock protein (HSP) 90 inhibitors, Akt inhibitors, 
histone deacytelase (HDAC) inhibitors, BCL2 inhibitors, pro-apoptotic peptides 
and other proteasome inhibitors are in preclinical studies to provide the framework 
for phase I and II clinical trials [83]. These new agents are tested singly or more 
commonly, in combination with other MM therapies. 
Microarray profiling showed that bortezomib induces HSP90 gene transcripts in 
MM cells [84]. The combination of Hsp90 inhibitor, 17AAG and bortezomib can 
block this stress response and increase cytotoxicity [85]. A clinical trial combining 
bortezomib and 17AAG is currently ongoing to see if the combination can 
overcome bortezomib resistance. 
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Bortezomib down-regulates ERK, Jak/STAT and PKC signaling pathways but 
activates the Akt survival pathway in vitro [86]. Hideshima et al. demonstrated that 
perifosine, an Akt inhibitor, when combined with bortezomib, is able to abrogate 
this response and induce synergistic MM cytotoxicity in vitro [83]. A phase II 
clinical trial is currently evaluating this combination. 
Other important new combinations are the HDAC inhibitors SAHA or LBH589 with 
bortezomib. The HDAC inhibitors are able to block protein degradation through the 
aggresome autophagy pathway and upregulate proteasomal degradation; 
conversely, blockade of the proteasome with bortezomib upregulates aggresome 
activity [84-85]. Preclinical studies have shown that combinations that block both 
pathways of protein degradation induce synergistic cytotoxicity in MM. A phase II 
trial of LBH589 is now ongoing in MM, with a combination LBH589 and bortezomib 
trial to follow. Richardson et al. [89] had reported modest single agent activity of 
SAHA in a phase I trial in 11 advanced MM patients and we are currently awaiting 
results of a combination trial involving SAHA and bortezomib. 
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Specific background 
7. Personalized therapy 
Personalized therapy, contrary to popular belief, it is not a new and modern 
concept. Personalized medicine has always been present in medicine, and 
observations of individual differences in response to food and drugs date back to 
as early as the 6th century BC. Pythagoras first made the observation that some 
individuals fall ill after ingesting uncooked fava beans, and disallowed his followers 
to eat them. It was not until the 1950s that the link between glucose-6-phosphate 
dehydrogenase deficiency, haemolytic anemia, and fava beans was established 
[90]. 
We have long recognized that each patient is unique in clinical presentation, 
prognosis, treatment tolerance, supportive care needs, and outcomes. We now 
recognize that, just as each patient is different in how he or she is affected by 
cancer, each cancer has a distinctive biology and natural history, and every 
disease called “cancer” comprises smaller subsets with distinctive features and 
differing outcomes that require personalized treatment plans [91]. 
 
8. Pharmacogenetics and pharmacogenomics 
Pharmacogenetics and pharmacogenomics deal with the role of genetic 
factors in drug effectiveness and adverse drug reactions. These disciplines have 
their origin in the 1950s with the emergence of human biochemical genetics. The 
role of genetics, as a potential cause of adverse drug reactions was set out in a 
first review by Motulsky in 1957 with the programmatic title “Drug reaction, 
Enzymes and biochemical Genetics”. The term, pharmacogenetics was coined by 
Friedrich Vogel from Heidelberg in 1959. In the late 1960s, Vessel showed 
remarkable similarity of disposal for several drugs in identical twins who shared 
100% of their genes, opposed fraternal twins who only share 50% [92]. The 
development of pharmacogenetics over the years remained slow since relatively 
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few drug responses or adverse drug reactions were under control of a single gene. 
Family studies were difficult and a direct DNA study of drug response was not yet 
possible. There was little or no impact on clinical pharmacology, drug development 
and clinical medicine. The increasing availability of DNA technology and in vitro 
molecular tests advanced the field. Pharmacogenetic research has seen an 
explosion of interest in the last decades by physicians, geneticists and the 
pharmaceutical industry, as reflected by the rapid increase in the number of 
publications in the medical literature [93].  
The term pharmacogenomics was introduced in 1990s with the emergence of the 
Human Genome project and the development of the genome sciences [94-95]. 
New technology such as microarrays allowed search for multiple genes affecting 
drug responses. The analysis of DNA abnormalities that characterize a disease is 
now leading to therapeutic drugs acting on disease-specific DNA mutations [96]. 
After the completion of the Human Genome Project in 2003, genomics has 
become a mainstay of biomedical research and pharmacogenetics has been 
forecasted to be one of the first clinical applications arising from the new 
knowledge [97]. Indeed, the research efforts in the field of pharmacogenetics 
expressed as the number of publications listed on PubMed have steadily 
increased until levelling out in 2009 at 1100-1200 publication per year [98]. By 
contrast, the clinical use of pharmacogenetic testing did not meet the initial high 
expectations and has lagged considerably behind, despite the significant body of 
evidence supporting its usefulness. As a result of the unmet promises many 
clinicians have become somewhat disillusioned regarding pharmacogenetics in 
recent years. Indeed, expectations of the effect of a single polymorphism on drug 
response were unrealistically high [99]. Still, pharmacogenetics holds the promise 
of advancing drug therapy. The ultimate goal of pharmacogenetics is personalized 
medicine, rather than the established “one size fits all” approach to drugs and 
dosages, according to the specific genetic make-up of a given patient. 
Environment, diet, age, lifestyle and state of health can all influence the individual 
response to the pharmacological treatment, but understanding the influence of 
genetics could be the key to create personalized medicine: selecting the right drug 
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and administering it at the dose that have the maximum efficacy and the least 
toxicity. 
Pharmacogenetics and pharmacogenomics combines traditional 
pharmaceutical sciences such as biochemistry with modern genetics. In particular, 
biotechnology and molecular biology of our days let us look inside our genetic 
code. Today, physicians can perform some impressive feats that were just exciting 
new ideas in research 10 years ago. A clinician can cure a woman with human 
epidermal growth factor receptor 2 gene-amplified breast cancer, by adding 
trastuzumab to standard adjuvant chemotherapy. Just after lunchtime, the same 
clinician can review a report of the results of polymerase chain reaction tests on 
DNA in the peripheral blood of an asymptomatic patient with chronic myelogenous 
leukemia (CML) and if necessary, change the patientʼs prescription from imatinib 
to dasatinib or nilotinib to maintain the patientʼs clinical remission. At the end of 
the day, a patient with KRAS–mutated metastatic colorectal cancer can be saved 
from unnecessary toxicity and cost by discussing whether to proceed with 
cetuximab or panitumumab treatment [100]. This is just few examples of how 
understanding SNPs could greatly benefit the therapeutic index of a patient. 
Currently The American Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) have approved more than 77 drugs with 
pharmacogenomic information into drug label inserts [100,101]. 
In Table 2 are reported some significant examples of pharmacogenomics 
biomarkers, describing prevalence, and authority guidelines [101,102]. 
 
Table 2. Example of pharmacogenomic biomarkers in the context of disease, and 
authority guidelines
 
Drug Indication Causative genotype and its 
effects 
Clinical Directive on Label 
Abacavir      
(Ziagen, 
GlaxoSmithKline) 
HIV-1 HLAB*5701  
Hypersensitivity 
Black-box warning: “Prior to initiating 
therapy with abacavir, screening for 
the HLAB*5701 allele is 
recommended.“Your doctor can 
determine with a blood test if you 
have this gene variation. 
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Azathioprine 
(Imuran, 
Prometheus) 
Renal allograft 
transplantation, 
rheumatoid  
arthritis 
TPMT*2, TPMT*3A, and 
TPMT*3C 
Severe myelotoxicity 
“TPMT genotyping or phenotyping 
can help identify patients who are at 
an increased risk for developing 
Imuran toxicity.”“Phenotyping and 
genotyping methods are 
commercially available.” 
Carbamazepine 
(Tegretol, Novartis) 
Epilepsy, 
trigeminal 
neuralgia 
HLAB*1502  
Stevens-Johnson syndrome or 
toxic epidermal necrolysis 
Black-box warning: “Patients with 
ancestry in genetically at-risk 
populations should be screened for 
the presence of HLAB*1502 prior to 
initiating treatment with 
Tegretol.Patients testing positive for 
the allele should not be treated with 
Tegretol.” “For genetically at-risk 
patients, high-resolution HLAB*1502 
typing is recommended.” 
Cetuximab   
(Erbitux, Imclone) 
Metastatic 
colorectal 
cancer 
KRAS mutations 
Efficacy 
“Retrospective subset analyses of 
metastatic or advanced colorectal 
cancer trials have not shown a 
treatment benefit for Erbitux in 
patients whose tumors had KRAS 
mutations in codon 12 or 13. Use of 
Erbitux is not recommended for the 
treatment of colorectal cancer with 
these mutations.” 
Clopidogrel   
(Plavix,  
Bristol-Myers 
Squibb) 
Anticoagulation CYP2C19*2*3 
Efficacy 
“Tests are available to identify a 
patientʼs CYP2C19 genotype; these 
tests can be used as an aid in 
determining therapeutic strategy. 
Consider alternative treatment or 
treatment strategies in patients 
identified as CYP2C19 poor 
metabolizers.” 
Irinotecan 
(Camptosar, Pfizer) 
Metastatic 
colorectal 
cancer 
UGT1A1*28 
Diarrhea, neutropenia 
“A reduction in the starting dose by 
at least one level of Camptosar 
should be con- sidered for patients 
known to be homozygous for the 
UGT1A1*28 allele.” “A laboratory 
test is available to determine the 
UGT1A1 status of patients.” 
Panitumumab 
(Vectibix, Amgen) 
Metastatic 
colorectal 
cancer 
KRAS mutations 
Efficacy 
 “Retrospective subset analyses of 
metastatic colorectal cancer trials 
have not shown a treatment benefit 
for Vectibix in patients whose tumors 
had KRAS mutations in codon 12 or 
13. Use of Vectibix is not 
recommended for the treatment of 
colorectal cancer with these 
mutations.” 
Trastuzumab 
(Herceptin, 
Genentech) 
HER2-positive 
breast cancer 
HER2 expression 
Efficacy 
“Detection of HER2 protein 
overexpression is necessary for 
selection of patients appropriate for 
Herceptin therapy because these are 
the only patients studied and for 
whom benefit has been shown.” 
“Several FDA-approved commercial 
assays are available to aid in the 
selection of breast cancer and 
metastatic gastric cancer patients for 
Herceptin therapy.” 
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Warfarin  
(Coumadin,     
Bristol-Myers 
Squibb) 
Venous  
thrombosis 
CYP2C9*2*3 and VKORC1 
Bleeding complications 
Includes the following table: Range 
of Expected Therapeutic Warfarin 
Doses Based on CYP2C9 and 
VKORC1 Genotypes. 
 
 
8.1. Basic principles of pharmacogenetics 
By definition, pharmacogenetics refers to the study of inherited differences 
(variation) in drug metabolism and response. On the other hand 
pharmacogenomics refers to the general study of all of the many different genes 
that determine drug behavior. The distinction between the two terms is considered 
arbitrary, however, now the two terms are very often used interchangeably [103]. 
A gene is a part of the DNA that codes for a type of protein or for a RNA chain that 
has a specific function in the organism. There are two alleles per autosomal gene 
(one paternal and one maternal). Together the two alleles form the genotype. 
Heterozygotes have two different alleles, and homozygotes have two of the same 
alleles. Genetic variation can consist of deletions, insertions, inversions, and copy 
number variation [104]. Most sequence variations are single nucleotide 
polymorphisms (SNPs), a single DNA base pair substitution that may result in a 
different gene product. As a result of this genetic variation many genes have 
multiple variants. The most common allele in a population is referred to as the wild 
type. Some of the variant alleles code for non-functional or decreased functional 
proteins. Allele frequencies can vary greatly in different ethnic populations. 
Phenotype refers to the trait resulting from the protein product encoded by the 
gene. 
 
8.2. Single nucleotide polymorphisms (SNPs) 
Polymorphisms are genetic variations that occur with different frequency in 
different populations. These variations could be represented by insertion or 
deletion, but the most common variations are SNPs. A SNP is a DNA sequence 
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variation occurring when a single nucleotide in the genome differs among 
members of a species or between chromosomes in an individual. In the human 
genome the number of SNPs is estimated around 3.2 millions and they are 
responsible for the 90% of genetic human variability (105). SNPs are classified in 
three groups depending on where they are located in the genome: (i) c-SNP, 
variations located in coding region , exons, whose presence could modify or not 
the amminoacidic sequence of the protein (non synonymous and synonymous, 
respectively), (ii) p-SNP, located in perigenic region and (iii) r-SNPs, random SNPs 
that are located in the intragenic region (Figure 10). 
Polymorphisms in key genes encoding drug transporters and metabolizing 
enzymes influence intracellular drug delivery. Pharmacogenetics has indeed 
proven to be a potential source of biomarkers able to predict drug response and 
adverse drug reactions. 
 
 
 
Figure 10. Single nucleotide polymorphisms classification depending on their position in 
the genome. 
 
Currently, pharmacogenetic information is accumulating rapidly and it was 
reported that based on the available pharmacogenetic information it is possible to 
generate advice for nearly 100 drugs for a patient with a completely sequenced 
genome [106]. To date, many efforts within the field of pharmacogenetics have 
been aimed at the improvement of drug therapy with “high risk” medications such 
as within the field of oncology. Yet the clinical use of genotyping prior to drug 
prescription and dispensing is not widely practiced, largely by a lack of scientific 
evidence for improved patient care by pharmacogenetic testing [107]. 
Promoter   exon        intron 
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several “players” can be identified [108], including the biotechnology and analytical 
industry, the pharmaceutical industry, research institutions, funding agencies, 
regulatory agencies, clinicians, and patients. These players each have substantial 
roles, both individually and in collaboration, in developing and implementing 
clinical applications of pharmacogenetics. Initiatives have been proposed such as 
a pharmacogenetic research network that includes a series of integrate groups 
with expertise in pharmacology, genomic science, bioinformatics and clinical 
science. The group located at Stanford University is responsible for the 
development of a public database that focuses on genotype and phenotype data 
relevant to pharmacogenomics. The Royal Dutch Association for the 
Advancement of Pharmacy established the Pharmacogenetics Working Group in 
2005, a 15-member multidisciplinary working group, comprising clinical 
pharmacists, physicians, clinical pharmacologists, clinical chemists, 
epidemiologists, and toxicologists are represented. This ore only two example of 
what it is moving on this panorama. 
The pharmacogenomics studies require a large number of subjects and multi-
disciplinary teams with complementary expertise, as well as the ability to genotype 
a very large number of polymorphisms and haplotypes, frontier joined with 
Genome Wide Associations Studies (GWAS) [109]. The main current problems 
related to pharmacogenomics are: poorly defined phenotypes; studies of non-
functional mutations; ethical aspects such as the use of genomic information; 
unclear sources for covering diagnostic costs and lack of founding for large 
prospective randomized studies and not only retrospective studies. 
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Aim of the study 
With the advent of novel therapies, patients with MM are enjoying a longer 
survival. Bortezomib as a single agent, has been shown to be an highly effective 
treatment against cancer cells, and unlike most anticancer agents, bortezomib is 
effective against MM even when MM cells have already showed multi drug 
resistance. Bortezomib is unique because it enhances the sensitivity of cancer 
cells to other treatment drugs. Therefore, the trend is to combine bortezomib with 
other conventional agents, such as dexamethasone, thalidomide, doxorubicin and 
melphalan and novel agents, such as lenalidomide. In addition, there are other 
clinical trials looking at the combination of bortezomib with other investigational 
agents. The reason that bortezomib is used in so many different combinations is 
that it is a very effective agent in MM. Despite many phase II and III studies show 
favorable results in treating MM, the treatment outcome for patients are often 
varied and difficult to predict, and more and more patients are relapsing to the 
treatment. 
The general aim of my three-years research period was to investigate resistant 
mechanisms in MM with regard to bortezomib treatment. In particular, I have been 
focusing on the relationship between pharmacogenetics biomarkers and drug 
response, on the basis of an ex vivo approach. 
The main hypothesis of the work presented in this dissertation is that DNA 
damage repair pathways mediate resistance to agents used to treat MM - and 
other cancers in general - and that one of the proposed mechanisms of action for 
proteasome inhibitors, as bortezomib, is inhibition of DNA damage repair. 
Following the above mentioned hypothesis, the first objective was to conduct a 
retrospective study in a subset of 454, previously untreated, MM patients enrolled 
in a randomized phase III open-label study, and to investigate a panel o SNPs in 
DNA repair and Folate pathway genes, as candidate for bortezomib 
responsiveness. 
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There are indications that overexpression of P-gp may contribute to resistance 
to bortezomib. For example it has been shown that knockdown of P-gp 
resensitises leukaemia cells to proteasome inhibitors. Despite these important 
mechanisms of resistance little is known about the interaction of bortezomib with 
P-gp. For this reason, the second objective was to demonstrate that bortezomib 
is a P-gp substarte in an in vitro model and subsequently we investigated if SNPs 
in ABCB1, coding for P-gp, may contribute to the phenomenon of bortezomib 
resistance. 
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Materials and methods 
9. Materials and methods - first objective  
SNPs in DNA repair and Folate pathway genes, as candidate for 
bortezomib responsiveness in newly diagnosed MM patients 
 
9.1. Study population 
A total of 454 MM patients were retrospectively enrolled in this 
pharmacogenetic study. These patients represented a subset of a randomized 
phase III trial, on V-TD vs TD in newly diagnosed and previously untreated MM 
patients [110]. Their selection was based exclusively on availability of a written 
informed consent for correlative sub-studies, according to the Helsinki Declaration 
and later Amendments. The study was approved by all local ethical committees of 
the 73 hospitals of the GIMEMA (Gruppo Italiano Malattie EMatologiche 
dellʼAdulto) Myeloma Network in Italy involved in the study. In Figure 11 (modified 
from Cavo et al., [110]) is summarized the treatment protocol. 
 
9.2. Evaluation of bortezomib response 
Laboratory and clinical investigations, done to assess response in the 
population of interest, are described in a comprehensive manner by Cavo et al., 
[110]. Bone marrow biopsy and aspirate samples were obtained at baseline, at 
pre-specified time-points, and as needed to confirm complete response. Response 
and progression were reported by investigators according to criteria of the 
European Group for Blood and Marrow Transplantation [111], with the addition of 
categories for near complete response (100% reduction in M protein according to 
electrophoresis, but immunofixation positive) [63] and very good partial response 
(≥90% reduction in serum M protein, and less than 100 mg urine M protein per 
day) [112]. Patients with complete response who lacked confirmation from bone 
marrow biopsy samples were centrally downgraded to very good partial response. 
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Figure 11. Trial design [G-CSF: granulocyte colony-stimulating factor] 
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9.3. DNA extraction 
DNA was extracted from a fresh fraction of plasma cells using QIAamp® DNA 
Mini Kit (Quiagen, Hilden, Germany). For several samples DNA extraction was 
also carried, following the same procedure, from peripheral blood. The kit provides 
a fast and easy method for DNA purification from whole human blood, 
lymphocytes, plasma, serum, and body fluid and sample may be either fresh or 
frozen. After treatment with lysis buffer, the kit provides proteinase K, commonly 
used to digest proteins, to remove contamination and inhibits nucleases that might 
degrade DNA. The lysate buffering conditions are adjusted to allow optimal 
binding of the DNA to the silica membrane of the QIAamp spin column. To 
improve the purity of the eluted DNA membranes were washed two times with two 
different washing buffers (Buffer AW1 and Buffer AW2). Purified DNA was finally 
eluted from the membrane in a concentrated form in Buffer AE. All the passages 
for DNA isolation were performed following the protocol provided with the kit. The 
material collected was stored at -20°C. 
 
9.4. DNA quantification 
The DNA quantification was performed using NanoVueTM, an innovative 
spectrophotometer able to measure small volumes of very concentrated or highly 
absorbing samples. Nucleic acids were quantified at 260 nm. DNA quality was 
also evaluated quantifying the absorbance (A) at 260 and 280 nm. All samples 
gave a A260/A280 ratio greater than 1.8, indicating that the DNA is reasonably clean 
of proteins that could intefere with downstream applications. 
 
9.5. Genotyping analysis 
Genotypes were determined by PCR following the restriction fragment length 
polymorphism (RFLP) and/or the real-time PCR approach according to published 
methods or as recommended by manufacturer. The genotype results were 
regularly confirmed by repetition of 100% of the samples. Positive and negative 
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controls were included in each reaction as quality control. In addition, accuracy of 
genotyping was confirmed by repetition of 100% of the samples. The replicates 
were 100% concordant. 
 
9.6. PCR RFLP 
The principle components (Table 3) to perform a PCR are primers, containing 
sequences complementary to the target region, DNA polymerase, necessary to 
enzymatically assemble a new strand of DNA, deoxynucleoside triphosphates 
(dNTPs), from which the DNA polymerases synthesize a new DNA strand, buffer 
solution and usually divalent cations that help the reaction (usually MgCl2). 
 
Table 3. Principle components to perform PCR 
 
Components Final concentration 
Water 0.52X 
10X Buffer 1X 
MgCl2 solution 2.00 mM 
dNTPs 0.15 mM 
Forward primer 0.13 µM 
Reverse primer 0.13 µM 
Taq polymerase 0.03 U/µL 
 
 
DNA was added at this mixture and the thermal cycling program was performed. 
The DNA is replicated in every cycles and the amount increased exponentially. 
After the amplification of the sequence of interest, the appropriate restriction 
enzyme was used to recognize, if present, the restriction site creating DNA 
fragments. The fragments obtained after incubation with the restriction enzyme 
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(usually 37°C, overnight) were separated through electrophoresis at 200 V for 30 
minutes, on pre-cast polyacrilamid gels 10% TBE (BIO RAD, Hercules, CA, USA). 
The DNA was then analyzed using ethidium bromide, an intercalating agent 
commonly used as a fluorescent tag. When exposed to UV ray, its fluorescence is 
20-fold higher after binding DNA. The image of the gel was acquired using a digital 
photo camera connected to VERSADOC-4000 (BIO RAD) and visualized with 
QUANTITY ONE software. Three were the possible situation that can merge from 
the analysis: homozygosis for the wild type (wt) allele, homozygosis for the SNP or 
hetherozigosis, in which only one of the two alleles presents the SNP and the 
other one is wt. 
 
9.7. Real Time PCR 
Real time PCR or quantitative PCR is a variation of the standard PCR 
technique used to quantify DNA or mRNA in a sample. Using sequence specific 
primers, the relative number of copies of a particular DNA or RNA sequence can 
be determined. Quantification of amplified product is obtained using fluorescent 
probes and specialized machines that measure fluorescence while performing 
temperature changes needed for the PCR cycles. More specifically for our use, an 
allelic discrimination assay was used to detect variants of a single nucleic acid 
sequence. The presence of two primer/probe pairs in each reaction allows 
genotyping of the two possible variants of a polymorphism site in a target template 
sequence. One fluorescent dye detector is a perfect match to the wt (allele 1) and 
the other fluorescent dye detector is a perfect match with the SNP allele (allele 2). 
The allelic discrimination assay classifies unknown samples as: i) homozygotes 
(samples having only allele 1 or allele 2) and ii) heterozygotes (samples having 
both allele 1 and 2). The allelic discrimination assay measures the change in the 
fluorescence of the dyes associated with the Taqman probes VIC® and FAMTM 
(Applied Biosystems, Foster City, CA), that selectively bind wt or SNP allele. The 
reaction was prepared using 10 ng DNA, 20X or 40X Taqman genoyping assay 
mix, 2X Taqman®Universal Master Mix, No AmpErase®UNG and water RNAse 
free, for a total volume of 25 µL. Each reaction was run in presence of a negative 
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control, no template control (NTC). The analysis was performed using Real Time 
PCR System 7300 (Applied Biosystems). Three were the steps performed for the 
allelic discrimination with Taqman probes: i) a pre-read run, using an allelic 
discrimination plate that measures the fluorescence at the baseline; ii) an 
amplification run, using a standard curve plate document to generate real-time 
PCR data that consist in 95°C for 10 min, 40 cycles at 92°C for 15 sec and 60°C 
for 1 min and, finally, iii) an allelic discrimination run (post-read run), using the 
allelic discrimination plate to analyze the data and discriminate the genotype, after 
removing the baseline fluorescence. Allelic discrimination assays use the 
fluorogenic 5ʼ nuclease chemistry: fluorigenic probes, reporter (R), are used to 
detect specific PCR product as it accumulates during the PCR cycles. Additionally, 
the two probes at the 3ʼend bind the quencher (Q) and a minor groove binder 
(MGB) to improve the probe affinity for the target DNA. The process could be 
described in 4 passages: i) polymerization: R and Q are attached to the 5ʼ and 3ʼ 
end of a probe; ii) strand displacement, when both dyes are attached to the probe, 
R dye emission is quenched; iii) cleavage, during each extension cycle: the DNA 
polymerase system cleaves the R dye from the probe, iv) completion of 
polymerization: the R dye emits its characteristic fluorescence (Fig. 12). The signal 
is extremely specific because the probes do not interfere and the fluorescent 
signal is present only when the binding between probes and target DNA is correct. 
 
Figure 12. Molecular basis for TaqMan-based allelic discrimination. 
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The tables below shows the polymorphisms analyzed for each gene and the 
methods used for the analysis (Table 4-6). 
 
Table 4. Details on investigated SNPs in DNA repair genes.
 
Gene 
 
rs unique code 
[amino acid change or non-coding region] 
Method* 
APEX1  
  rs1130409 [Asp148Glu] 
 
RFLP [113] 
 
RT TaqMan assay C_8921503_10 
 
hOGG1  
  rs1052133 [Ser326Cys] RFLP [114] 
 
RT TaqMan assay C_3095552_1 
 
NBS1  
  rs1805794 [Gln185Glu] RFLP [115] 
 
XPD  
  rs1799793 [Asp312Asn] RT TaqMan assay C_3145050_10 
 
  rs13181 [Lys751Gln] RFLP [116] 
 
RT TaqMan assay C_3145033_10 
 
XRCC1  
  rs861539 [Gln399Arg] RFLP [116] 
 
RT TaqMan assay C_622564_10 
 
XRCC3  
  rs861539 [Thr241Met] RFLP [116] 
 
RT TaqMan assay  
C_3145033_10 
 
XPA  
  rs1800975 [5ʼ UTR region] RT TaqMan assay C_482935_1_ 
 
  rs2808668 [Intronic region] RT TaqMan assay C_9312100_20 
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XPC  
  rs2228000 [Ala499Val] RT TaqMan assay C_16018061_10 
 
  rs2228001 [Gln902Lys] RT TaqMan assay C_234284_1_ 
 
*RFLP = PCR-RFLP analysis carried out according to published methods (reference 
parenthetically); RT = Real-Time PCR with TaqMan allelic discrimination assay (Applera, Foster 
City, USA); 
 
Table 5. Details on investigated SNPs in folate metabolic pathway genes.
 
Gene 
 
rs unique code 
[amino acid change or non-coding region] 
Method* 
DHFR !
  rs70991108 [Intron 1] PCR/electrophoresis [117] 
 
FOLR1 !
  rs2071010 [5' UTR region] RT TaqMan assay  
C_15861044_10 
 
MTHFR !
  rs1801133 [Ala222Val] RFLP [118] 
 
! RT TaqMan assay  
C_8714009_10 
 
  rs1801131 [Glu429Ala] RFLP [118] 
 
! RT TaqMan assay  
C_850486_20 
MTR !
  rs1805087 [Asp919Gly] RFLP [119] 
 
! RT TaqMan assay  
C_12005959_10 
MTRR !
  rs1801394 [Ile49Met] RFLP [120] 
 
RT TaqMan assay  
C_3068176_10 
 
  rs1532268 [Ser175Leu] RT TaqMan assay  
C_3068164_10 
 
  rs162036 [Lys350Arg] RT TaqMan assay  
C_3068152_10 
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MTRR  
  rs10380 [His595Tyr] RT TaqMan assay  
C_7580070_1 
 
RFC !
  rs1051266 [Arg27His] RFLP [121] 
 
SHMT !
  rs1979277 [Leu474Phe] RFLP [122] 
 
RT TaqMan assay  
C_3063127_10 
 
TYMS !
  rs45445694 [enhancer region] PCR/electrophoresis [123] 
* PCR/electrophoresis and RFLP = PCR-RFLP analysis carried out according to published 
methods (reference parenthetically); RT = Real-Time PCR with TaqMan allelic discrimination assay 
(Applera, Foster City, USA);  
 
Table 6. Details on investigated SNPs in ABCB1 gene.
 
Gene 
 
rs unique code 
[amino acid change or non-coding region] 
Method* 
ABCB1  
  rs10245483 [Promoter region] RT TaqMan assay 
 C_2573447_20 
 
  rs3213619 [Promoter region] RT TaqMan assay 
C_27487486_10 
 
  rs1128501 [Gly185Val] RT TaqMan assay 
C_7586664_10 
 
  rs1128503 [Gly412Gly] RT TaqMan assay 
C_7586662_10 
 
RFLP [Goreva et al., 2004] 
 
  rs60023214 [Ile1145Ile] RFLP [124]  
 
  rs2032582 [Ser893Thr or Ser893Thr] RFLP [125] 
 
*RFLP = PCR-RFLP analysis carried out according to published methods (reference 
parenthetically); RT = Real-Time PCR with TaqMan allelic discrimination assay (Applera, Foster 
City, USA); 
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9.8. Statistical analysis 
Genotypes distribution, in the overall population was tested for Hardy-
Weinberg equilibrium (HWE) with exact test. Additive models, with SNPs 
represented as number of minor allele (0, 1 or 2), were used to assess association 
between individual SNPs and treatment outcome after 4 months of induction 
therapy. Relative risk (RR) and 95% CI were estimated with Cox proportional 
hazard models and evaluated with likelihood ratio tests. All statistical tests were 
two-sided, with statistical significance defined as P = 0.05. Statistical analyses 
were conducted using SAS version 9.1 (SAS Institute Inc., Cary, NC). 
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10. Materials and methods - second objective 
Bortezomib as P-gp substrate and ABCB1 variants candidate for 
bortezomib responsiveness in newly diagnosed MM patients 
 
10.1. Bi-directional transport studies 
10.1.2. Materials  
MDCK–MDR1, MDCK Caco-2 cell lines and all components necessary for 
proper cell culture growth conditions (described below) were purchased from the 
University of California, San Francisco Cell Culture Facility (San Francisco, CA). 
Bortezomib was obtained from LC Laboratories. GG918 (GF 120918: N-[4-[2-
(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-
methoxy-9-oxo-4-acridinecarboxamide) was a kind gift from GlaxoSmithKline, 
Research Triangle Park, NC). Falcon PET cell culture inserts (pore size 0.4 μm, 
diameter 4.2 cm2) and Costar six-well plates were obtained from Fisher Scientific 
(Santa Clara, CA). All solvents were HPLC grade and were obtained from Fisher 
Scientific. 
 
10.1.3. Cell Cultures  
Caco-2 cells were grown in a humidified 5% CO2 atmosphere at 37ºC using 
minimal essential medium (MEM) Eagleʼs with Earleʼs balances salt solution (BSS) 
containing: 2 mM L-glutamine, 5.5 mM glucose, and 2.2 g/L sodium bicarbonate 
(NaHCO3), which was supplemented with 1.0 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, and 10% of heat-inactivated FBS (custom made from 
the UCSF Cell Culture Facility), 100 U/mL penicillin and 100 U/mL streptomycin. 
Cells were grown to 90-100% confluence and harvested using 0.05% trypsin 
EDTA. Monolayers were prepared by seeding harvested cells onto inserts at a 
density of 250,000 cells/insert. Growth medium for the Caco-2 was refreshed 48 
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hours post-seeding and then twice weekly, including one day prior to the 
experiment. Caco-2 cell monolayers were used for bidirectional transport 
experiments 21-28 days post-seeding. 
MDCK cells were grown in a humidified 5% CO2 atmosphere at 37ºC using 
Dulbeccoʼs modified Eagleʼs medium supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (custom made from the UCSF Cell Culture Facility), 100 
U/mL penicillin and 100 U/mL streptomycin; 1% of nonessential amino acid. 
MDCK–MDR1 cell culture medium was as described above with addition of 80 
ng/mL colchicine as a selective supplement. Cells were grown to 90-100% 
confluence and harvested using 0.25% trypsin EDTA. Monolayers were prepared 
by seeding harvested cells onto inserts at a density of 250,000 cells/insert, and 
maintained for 7 days before the experiment. Fresh media was added to the cells 
3 days after seeding and 24 h before the transport study. 
 
10.1.4. Bidiretional Transport Experiments 
The transport assays were performed following a modified protocol previously 
described. [126] 
Cell monolayers were preincubated in transport buffer (Hankʼs buffered salt 
solution containing 25 nM HEPES and 1% FBS, pH 7.4) at 37ºC for 20 min. 
Transepithelial electrical resistance (TEER) values were measured across the 
monolayerʼs using a Millicell (Millipore Corporation, Bedford, MA) equipped with 
chopstick electrodes (Figure 13). Approximate MDCK TEER values were 200 to 
250 Ω cm2, MDCK–MDR1 values ranged from 900 to 1300 Ω cm2, and Caco-2 
values ranged from 240 to 320 Ω cm2. 
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Figure 13. Millicell (Millipore Corporation, Bedford, MA) equipped with chopstick 
electrodes for TEER measurement 
 
All experiments were performed in triplicate. In the case of the MDCK-MDR1 and 
parental MDCK cells, both these transfected and control cell lines were run on the 
same day to account for potential between-day variability of LC-MS/MS 
measurement and TEER values. 
To measure P-gp effect in mediated transport, solutions were prepared containing 
1μM drug in Hankʼs buffered salt solution modified and compared further to 
bidirectional transport with and without GG918, a P-gp inhibitor. To measure A!B 
transport, 1.5 mL of drug solution was added to the apical side (A) and 2.5 mL of 
Hankʼs buffered salt solution to the basolateral side (B). B!A transport was 
evaluated adding 2.5 mL of drug in B side and 1.5 mL of Hankʼs buffered salt 
solution in A side. To evaluate P-gp effect, the same procedure above was used 
adding 500 nM of GG918 in both sides. All experiments were run at 37ºC with a 
shaking speed of 25 strokes/minute in the Boekel Shake ʻNʼ Bake Incubator 
Shaker II (Boekel Scientific, Feasterville, PA). 
Cells were incubated in a 37,5 ºC shaker, and 200 μL aliquots were taken from the 
receiver side at 1, 2, and 3 h time intervals. At the first two time points, 200 μL 
was replaced with fresh receiver solution to maintain the original starting volumes. 
After the last time point, the apical solution was removed by suction, and each 
filter was dipped in three different beakers containing large volumes of ice-cold 
phosphate-buffered saline. The inserts were inverted to remove residual liquid. 
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When dried, membranes were removed from the inserts and sonicated (in an 
ultrasonic bath) in 1mL of 25% ACN for 15 min. This volume was than centrifuged 
for 10 min at 10,900g, and the resulting supernatant was analyzed by LC/ MS/MS 
as well as all 200 μL aliquots. 
 
10.1.5. Measurement of bortezomib by LC-MS/MS 
An API 4000 using Electrospray/positive ionization was employed. Multiple 
Reaction Monitor (MRM) was set at 367.008-226.129 m/z for bortezomib and 
237.01-194.02 m/z for carbamazepine, CBZ, (internal standard). The column was 
Phenomenex, Gemini, C18 (100 mm x 2 mm, 5 μm particle size) with a mobile 
phase consisting of A, 99.9% H2O containing 0.1% formic acid and B, 99.9% ACN 
containing 0.1% formic acid. 
The gradient program was as follows: 0–6 min, B, 25–90%; 6.01–8 min, B, 25%. 
The flow rate was 0.5 mL/min. Running time for each sample was 8 min.  
 
10.1.6. Data analysis 
The apparent permeability (Papp) values (cm/s) were calculated as follows, 
where the rate of transport was measured from the flux of drug across the cells 
(ng/h). 
Papp = Rate of transport/(surface area x initial donor concentration) 
Efflux ratio was defined as the ratio of basolateral to apical (B!A) over apical to 
basolateral (A!B) transport. 
10.1.7. Statistical analysis 
Experimentally derived in vitro data are shown as mean ± SD (n=3). Studentʼs 
t-test was used to analyze differences between two groups. The p-value for 
statistical significance was set at <0.05.  
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10.2. Identification of P-gp in MM cells  
The cell line used was U-266, cells derived from human MM. They were 
cultured in RPMI 1640 medium with L-glutamine, sodium pyruvate, and Hepes 
buffer (ATCC), supplemented with 10% fetal bovine serum (FBS, Lonza, 
inactivated for 30 minutes at 57°C), 5% CO2-95% air at 37°C in cell incubator. The 
medium was supplemented with 1% penicillin (10.000 Units/mL)/streptomycin (10 
mg/mL) and replaced every 2 or 3 days to maintain a cells density of about 5*10^5 
cells/mL. 
Cells were exposed to increasing concentration of bortezomib (Aurogene,). The 
parental, sensitive cell line was maintained in parallel cultures without bortezomib 
to be used as control. Powder was stored at room temperature and a stock 
solution (10 mM) was prepared dissolving the drug in DMSO (1:6000). The 
starting treatment concentration of cells was 0.0125 µM. The medium was 
replaced every 2 or 3 days with the necessary bortezomib concentration. The 
resistance was observed when the cells acquired the ability to grow in the 
presence of a specific concentration of the drug. U266 resistant cells were 
collected at the following bortezomib concentrations: 0.0125 µM and 0.025 µM. 
The process required about 2 months. Proteins were collected from cells treated 
at each concentrations following the protocol described in Protein isolation 
(10.2.1.). 
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10.2.1. Protein isolation  
To isolate proteins Qproteome Mammalian protein Prep kit (QIAGEN, Hilden, 
Germany) was used. The lysis buffer was added with 10µL/mL of Protease 
inhibitor. Cells were washed with cold DPBS and treated with lysis buffer. The 
supernatant containing protein was stored at -80°C. Bradford solution was 
prepared using Protein Assay (Bio-Rad) and a standard curve was built using 
increasing concentration of BSA (Bovin Serum Albumin). Probes were measured 
at 595 nm in Photometer (Eppendorf) and the concentration obtained using the 
standard curve. 
10.2.2. Electrophoresis 
Gel electrophoresis was necessary to separate native or denatured protein by 
the length of the polypeptide or by the 3-D structure of the proteins. Protein probes 
were prepared at the concentration of 20 µg in 6.5 µL of Lysis Buffer. The marker 
used to identify protein was SpectraTM Multicolor Broad Range Protein Ladder 
(Fermentas) and the gels used were pre-cast 10% Bis-Tris Gel (Biorad) in 20x 
buffer (Biorad) running at 150 V. 
 
10.2.3. Western Blot 
Proteins were than transferred to a PVDF (Polyvinildifluoridon) membrane 
(0.45 µM, Millipore) where they were probed and than detected using antibodies 
specific to the target protein. 
The transfer from the gel to the membrane was done preparing the Blot-Sandwich. 
After the transfer, membranes were washed 5-10 minutes in TBS-T buffer on the 
shaker and then incubated 1 hour at room temperature with 5% milk, which blocks 
all remaining hydrophobic binding sites to prevent unspecific probing of the 
antibody. The membranes were then incubated with primary antibody, diluted in 
5% milk, 4°C overnight on the shaker. 
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Antibody Characterization Dilution 
Β-actine Mouse monoclonal IgG-1 
antibody (Anti-β-actin, Clone 
AC-15 Sigma) 
1:10 000 
P-gP Mouse monoclonal IgG-2a 
antibody (Clone C219 Enzo, 
Lörrach, Germany) 
1:250 
 
The membranes were washed three times, then incubated with secondary 
antibody diluted in 5% milk on the shaker. 
 
Antibody Characterization Dilution 
Anti-mouse Rabbit peroxidase conjugate 
IgG-A antibody. 
Rabbit-anti-mouse (Sigma) 
1:2000 
 
After washing the detection of proteins was done using ECLTM Western Blot 
Detection Reagent (GE Healthcare). 
 
10.3. Genotyping analysis 
Genotypes were determined by PCR following the restriction fragment length 
polymorphism (RFLP) and/or the real-time PCR following the methods described 
in chapter 9.1.  
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Results 
Demographic and disease characteristic at diagnosis of the overall population, 
and stratified by treatment are reported in Table 7. The Mean age at diagnosis is 
56.2 ± 7.2 year, confirming MM is principally a disease of the elderly [7]. 57% are 
male and 43% female; this is in accordance with the literature on MM in which is 
reported an higher frequency of the disease in males than females, independently 
from the race. Regarding myeloma subtype, 63.4% were IgG, 19.8% were IgA and 
15.8 harboured the light chain (BJ). The randomisation sequence was computer 
generated and was stratified by international staging system (ISS) disease stage 
[34]. 45.6% of the patients were in stage I, 37.7% in stage II, and 16.7% in stage 
III. Data on cytogenetic abnormalities, del(13q), t(4;14), and del(17p), detected by 
fluorescence in-situ hybridisation on highly purified bone marrow plasma cells, 
were available in more than 90% of patients. Cytogenetic abnormalities were not 
present in 203 patients (44.7%). 
Demographic and disease characteristics were well balanced between treatment 
groups at baseline (Table 7). 
 
Table 7. Demographic and disease characteristic at diagnosis in the overall 
population
 
 Overall (n 454) TD (n 230) V-TD (n 224) 
Age (years) 56.2 ± 7.2 55.9 ± 7.4 56.3 ± 6.9 
Mean ± SD (range) (23.1 - 66.3) (23.1 - 65.9) (34.5 - 66.3) 
Sex    
Male n (%) 259 (57.0%) 129 (56.1%) 130 (58.0%) 
Female n (%) 195 (43.0%) 101 (43.9%) 94 (42.0%) 
Myeloma subtype    
IgG n (%) 288 (63.4%) 144 (62.6%) 144 (64.3%) 
IgA n (%) 90 (19.8%) 50 (21.7%) 40 (17.6%) 
Light chain n (%) 72 (15.8%) 33 (14.3%) 39 (17.4%) 
Other n (%) 4 (1%) 3 (1.3%) 1 (< 1%) 
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ISS disease stage    
I 207 (45.6%) 104 (45.2%) 103 (46%) 
II 171 (37.7%) 87 (37.8%) 84 (37.5%) 
III 76 (16.7%) 39 (17.0%) 37 (16.5%) 
β2-microglobulin (mg/L)    
Mean ± SD (range) 3.4 ± 2.3  (0.2 - 15.7) 
3.8 ± 2.2  
(1.2 - 12.8) 
3.8 ± 2.5  
(0.2 - 15.7) 
Albumin (g/L)    
Mean ± SD (range) 3.8 ± 0.63  (1.8 - 5.4) 
3.8 ± 0.62  
(1.8 - 5.2) 
3.8 ± 0.63  
(2.1 - 5.4) 
Haemoglobin (g/L)    
Mean ± SD (range) 11.2 ± 1.9  (5.4 - 16.0) 
11.3 ± 2.0  
(6.0 - 16.0) 
11.1 ± 1.9  
(5.4 - 15.1) 
Platelets (!109 per L)    
Mean ± SD (range) 242.1 ± 83.6 (72 - 903) 
239.6 ± 75.6  
(74 - 644) 
244.7 ± 91.1 
(72 - 903) 
Bone marrow  
plasma cells  
Mean ± SD (range) 52.7 ± 23.7  (2 - 100) 
52.9 ± 24.3  
(2 - 100) 
52.5 ± 23.1  
(2 -100) 
Presence of del(13q) 193/230 * 97/119 96/111 
Presence of t(4;14) 83/339 * 47/182 39/182 
Presence of del(17p) 30/393 ** 17/199 13/194 
None 203 106 97 
 
* Missing data for 31 subjects; ** Missing data for 4 subjects 
 
Table 8 shows that rates of complete, near complete response and very good 
partial response were significantly higher after induction therapy with V-TD than 
with TD (P < 0.0001, RR 0.34, 95% CI 0.2 - 0.57). Also the overall response rate 
(ORR: Complete plus near complete response) was significantly higher after 
induction therapy with V-TD than with TD (P < 0.0001, RR 0.78, 95% CI 0.7 - 
0.86). Interestingly none of the patients assigned to the V-TD regimen had disease 
progression during induction therapy. On the contrary of the 49 patients belonging 
to the stable/progressive disease group in the TD regimen, 11 had disease 
progression during induction therapy. 
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Table 8. Treatment response in the overall population and according to treatment
 
  Overall TD V-TD 
Complete response 52 (11.4%) 11 (4.8%) 41 (18.3%) 
Near complete 45 (10.0%) 16 (6.9%) 29 (12.9%) 
Very good partial response 103 (22.7%) 36 (15.6%) 67 (29.9%) 
Partial response 189 (41.6%) 118 (51.3%) 71 (31.7%) 
Stable/Progressive disease 65 (14.3%) 49 (21.3%) 16 (7.1%) 
ORR 97 (21.4%) 27 (11.7%) 70 (31.2%) 
 
ORR: Complete plus near complete response. 
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11. Results - first objective 
SNPs in DNA repair and Folate pathway genes, as candidate for 
bortezomib responsiveness in newly diagnosed MM patients 
 
11.1. Treatment response according to polymorphisms in genes 
of the folic acid and DNA repair pathways. 
All the studied SNPs in both pathways (folic acid metabolism and DNA repair) 
were in Hardy-Weinberg equilibrium as demonstrated from the reported p value 
below. 
Table 9 shows distribution of polymorphisms in genes involved in the folic acid 
metabolism pathway in the overall population and in poor responder only. In the 
overall population frequency of the variant allele were as follow: RFC: 0.410 
(Hardy-Weinberg P = 0.648); FOLR: 0.053 (Hardy-Weinberg P = 0.918); MTHFR: 
0.425 (Hardy-Weinberg P = 0.656) and 0.329 (Hardy-Weinberg P = 0.615) for 
rs1801133 and rs1801131 respectively; MTR: 0.189 (Hardy-Weinberg P = 0.952); 
MTRR: 0.459 (Hardy-Weinberg P = 0.926) for rs1801394, 0.333 (Hardy-Weinberg 
P = 0.730) for rs1532268, 0.151 (Hardy-Weinberg P = 0.881) for rs162036 and 
0.129 (Hardy-Weinberg P = 0.813) for rs10380; SHMT1: 0.236 (Hardy-Weinberg P 
= 0.861); DHFR: 0.404 (Hardy-Weinberg P = 0.772); TS: 0.563 (Hardy-Weinberg 
P = 0.885) and 0.382 (Hardy-Weinberg P = 0.945) for rs45445694 and 
rs34489327 respectively. 
When stratifying the population according to poor response (very good partial 
response, partial response and stable/progressive disease; Table 9), we observed 
a significant association between poor responder after four months of induction 
therapy and MTFHR rs1801131 genotype (p = 0.0428), also after adjustment for 
treatment response (p = 0.0388). This finding, ascribe to MTHFR the role of 
prognostic factor for therapeutic outcome independently from the regimen.  
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Table 9. Treatment response in the overall population according to 
polymorphisms in genes of the folic acid pathway
 
Genes  Overall 
Population 
Poor 
Responders* p value 
RR  
(95% CI) p value 
RR (95% CI) 
Treatment 
adjusted  
RFC wt 152 116 0.696  0.778  
 He 232 185  1.04  (0.94-1.17)  
1.02  
(0.96-1.08) 
 SNP 70 56  1.05  (0.91-1.21)  
1  
(0.92-1.09) 
FOLR wt 406 316 0.322  0.644  
 He 44 37  1.08  (0.94-1.24)  
0.98  
(0.90-1.07) 
 SNP 2 2  -  - 
MTHFR 
rs1801133 wt 144 112 0.7668  0.8007  
He 234 187  1.03  (0.92-1.15)  
1.01  
(0.96-1.07) 
 SNP 76 58  0.98  (0.84-1.14)  
1.04  
( 0.9- 1.2) 
MTHFR 
rs1801131 wt 211 166 0.0428  0.0388  
He 187 154  1.05  (0.95-1.15)  
1  
(0.96-1.04) 
 SNP 56 37  0.84  (0.69-1.03)  
0.86  
(0.73-1.01) 
MTR wt 299 239 0.5219  0.99  
 He 138 104  0.94  (0.84-1.05)  
0.98  
(0.91-1.06) 
 SNP 17 14  1.03  (0.82-1.29)  
1.03  
( 0.8-1.33) 
MTRR 
rs1801394 wt 134 100 0.1825  0.3524  
He 223 175  1.05 (0.93-1.19)  
1.05  
(0.97-1.13) 
 SNP 97 82  1.13  (0.99-1.29)  
1.03  
(0.95-1.12) 
MTRR 
rs1532268 wt 206 166 0.1989  0.4339  
He 192 152  0.98  (0.89-1.08)  
0.97  
(0.93-1.02) 
 SNP 55 38  0.86  (0.71-1.04)  
0.98  
(0.83-1.15) 
MTRR 
rs162036 wt 328 256 0.8595  0.99  
He 113 90  1.02  (0.91-1.14)  
1.01  
(0.96-1.07) 
 SNP 12 10  1.07  (0.82-1.38)  
1.04  
(0.42-2.57) 
Results – first objective 
 53 
MTRR 
rs10380 wt 346 271 0.6264  0.99  
He 97 76  1  (0.89-1.13)  
1.01  
(0.95-1.07) 
 SNP 10 9  1.15  (0.93-1.42)  
1.03  
(0.29-3.67) 
SHMT1 wt 263 201 0.3962  0.5701  
 He 168 137  1.07  (0.97-1.18)  
1.02  
(0.97-1.07) 
 SNP 23 19  1.08 (0.89-1.32)  
0.97  
(0.86- 1.1) 
TS 
rs45445694 wt 85 65 0.7899  0.3704  
He 227 178  1.03  (0.89-1.18)  
1.02  
(0.96-1.09) 
 SNP 142 114  1.05  (0.91-1.21)  
0.98  
(0.91-1.07) 
TS 
rs34489327 wt 174 135 0.7326  0.4806  
He 212 166  1.01  (0.91-1.12) . 
1.03  
(0.98-1.09) 
 SNP 67 55  1.06  (0.92-1.21) . 
1.02  
(0.95- 1.1) 
DHFR wt 157 128 0.1564  0.5257  
 He 226 179  0.97  (0.88-1.07)  
0.98  
(0.93-1.02) 
 SNP 70 49  0.86  (0.72-1.02)  
0.96  
(0.88-1.06) 
 
* Poor responder: includes very good partial response, partial response and stable/progressive 
disease. 
 
When considering patients with stable/progressive disease as poor responder 
only, MTR genotype was associated with treatment response (Table 10). In 
particular the variant allele was associated with favourable response (p = 0.0281). 
However this association disappears after adjustment for treatment regimen (P = 
0.0505). 
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Table 10. Treatment response in the overall population according to 
polymorphisms in genes of DNA repair pathways
 
Genes 
 Overall 
Population 
Poor 
Responders* p value RR (95% CI)  
MTR wt 299 49 0.0281  
 He 138 16 . 0.71 (0.42-1.2) 
 SNP 17 0 . 0 (0 – 0) 
 
* Poor responder: stable/progressive disease. 
 
Table 11 shows distribution of polymorphisms in genes involved in the DNA repair 
pathway in the overall population and in poor responder only. In the overall 
population frequency of the variant allele were as follow: XPD: 0.416 (Hardy-
Weinberg P = 0.676) and 0.423 (Hardy-Weinberg P = 0.871) for rs1799793 and 
rs13181 respectively; XRCC1: 0.345 (Hardy-Weinberg P = 0.464); XRCC3: 0.412 
(Hardy-Weinberg P = 0.658); NBS1: 0.309 (Hardy-Weinberg P = 0.851); APEX1: 
0.384 (Hardy-Weinberg P = 0.604); hOGG1: 0.203 (Hardy-Weinberg P = 0.782); 
XPA: 0.326 (Hardy-Weinberg P = 0.698) for both rs2808668 and rs1800975 that 
are in complete linkage, as reported in the literature; XPC: 0.240 (Hardy-Weinberg 
P = 0.691) and 0.468 (Hardy-Weinberg P = 0.972) for rs222800 and rs2228001 
respectively. 
None of the other investigated SNPs in folic acid pathway or DNA repair pathway 
(Table 11) resulted associated with treatment outcome. 
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Table 11. Treatment response in the overall population according to 
polymorphisms in genes of DNA repair pathways.
 
Genes 
 Overall 
Population 
Poor 
Responders* p value 
RR  
(95% CI) p value 
RR (95% CI) 
Treatment 
adjusted  
xpd 
ex10 
  
wt 149 119 0.904  0.99  
He 232 181  0.98  (0.88-1.09)  
0.96  
(0.85-1.09) 
 SNP 73 57  0.98  (0.84-1.13)  
0.96  
(0.84- 1.1) 
xpd_ 
ex23 wt 149 114 0.2168  0.4851  
 He 226 185  1.07  (0.96-1.19)  
1.02  
(0.97-1.09) 
SNP 79 58  0.96  (0.82-1.13)  
0.98  
(0.88-1.09) 
xrcc1 wt 185 147 0.7501  0.99  
 He 225 174  0.97  (0.88-1.08)  
0.97  
(0.92-1.02) 
 SNP 44 36  1.03 (0.88-1.21)  
1.02  
(0.73-1.43) 
xrcc3 wt 151 120 0.4969  0.6811  
 He 232 185  1  ( 0.9-1.11)  
1.02  
(0.97-1.07) 
 SNP 71 52  0.92  (0.78-1.08)  
1.04  
(0.88-1.23) 
nbs1 wt 219 177 0.5442  0.99  
 He 189 145  0.95  (0.86-1.05)  
0.97  
(0.91-1.02) 
 SNP 46 35  0.94  (0.79-1.12)  
1.02  
(0.83-1.24) 
apex wt 165 126 0.2543  0.1395  
 He 229 187  1.07  (0.96-1.19)  
0.99  
(0.95-1.04) 
 SNP 60 44  0.96  (0.81-1.14)  
0.91  
( 0.8-1.03) 
hOGG1 wt 292 229 0.7424  0.99  
 He 140 112  1.02  (0.92-1.13)  
1.03  
(0.91-1.17) 
 SNP 22 16  0.93  (0.71-1.21)  
0.92  
(0.76-1.11) 
XPA 
rs2808668 wt 201 154 0.3827  0.2797  
 He 210 171  1.06  (0.96-1.17)  
1.04  
(0.99-1.09) 
 SNP 43 32  0.97  ( 0.8-1.18)  
1.04  
(0.88-1.22) 
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XPA 
rs1800975 wt 201 154 0.3827  0.2694  
 He 210 171  1.06  (0.96-1.17)  
1.04  
(0.99-1.09) 
 SNP 43 32  0.97  ( 0.8-1.18)  
1.04  
(0.88-1.22) 
XPC 
rs222800 wt 256 201 0.7153  0.7641  
 He 175 139  1.01  (0.92-1.12)  
0.98  
(0.94-1.03) 
 SNP 21 15  0.91  (0.69-1.2)  
1.02  
(0.8-1.3) 
XPC 
rs2228001 wt 127 105 0.2498  0.8382  
 He 225 177  0.95  (0.86-1.06)  
1  
(0.95-1.05) 
 SNP 98 72  0.89  (0.77-1.03)  
0.98  
( 0.9-1.07) 
 
* Poor responder: includes very good partial response, partial response and stable/progressive 
disease. 
 
Regarding the relationship between treatment response, we considered the 
outcome in the overall population and adjusted data for treatment regimen. 
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12. Results - second objective 
Bortezomib as P-gp substrate and ABCB1 variants candidate for 
bortezomib responsiveness in newly diagnosed MM patients 
 
12.1. Bidirectional transport studies 
 
12.1.1. Bidirectional transport in MDCK cells 
Transport profiles of 1μM bortezomib across MDCK cells in control and 
inhibitory conditions are depicted in Table 12 and Figure 14. 
 
Table 12. Bortezomib transport and inhibition across MDCK cell monolayer 
Cell line Condition 
Papp, cm/sec x 10-6 
Efflux ratio 
AtoB BtoA 
MDCK 
control 1.65±0.12**** 8.79±0.77** 5.33 
w/ 0.5 µM  
GG 918 3.43±0.05**** 5.48±0.24** 1.60 
Papp, permeability; A, apical side; B, basolateral side.  
****p < 0.0001, statistical difference observed, using paired, two-tailed t-test 
**p < 0.01, statistical difference observed, using paired, two-tailed t-test 
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Figure 14. Bortezomib transport and inhibition across MDCK cell at 1, 2, 3 hours time 
points. 
 
In both, control and inhibitory conditions, apparent permeability in direction  B!A 
was greater than A!B. To determine whether bortezomibʼs transport was 
polarized, transepithelial fluxes were measured in both directions. Efflux ratio 
(B!A/ A!B) in control transport buffer was 5.33 and reduced to 1.60 in presence 
of GG918 (0.5 μM) (Table 12). According to the results shown in Table 12 after 
inhibition of P-gp by GG918 there was a significant increase of Papp in the A!B 
direction and decrease in B!A. 
The intracellular accumulation increased in A!C direction after addition of GG918 
from 4.92 ng to 7.01 ng (Table 13). In B!C direction the intracellular accumulation 
increased after addition of GG918 but this change wasnʼt statistically significant. 
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Table 13. Bortezomib intracellular accumulation in MDCK cells 
Cell line Condition 
Drug accumulation, ng 
AtoC BtoC 
MDCK 
control 4.92±0.64* 2.92±1.57 
w/ 0.5 µM GG918 7.01±0.81* 4.64±0.81 
A, apical side; B, basolateral side; C, intracellular accumulation.  
*p < 0.05, statistical difference observed, using paired, two-tailed t-test.  
 
12.1.2. Bidirectional transport in MDCK–MDR1 cells  
In MDCK-MDR1, in control and inhibitory conditions, apparent permeability in 
direction B!A was greater than A!B (Table 14) (Figure 15). Addition of P-gp 
inhibitor decreased efflux ratio from 82.0 in control to 4.92 in inhibitory conditions. 
GG918 provoked 18-fold increase in apparent permeability in direction A!B. 
 
Table 14. Bortezomib transport and inhibition across MDCK-MDR1 cell monolayer 
Cell line Condition 
Papp, cm/sec x 10-6 
Efflux ratio 
AtoB BtoA 
MDCK-MDR1 
control 0.19±0.02** 15.6±1.4 82.0 
w/ 0.5 µM 
GG918 3.46±0.69** 17.0±2.3 4.92 
Papp, permeability; A, apical side; B, basolateral side. 
**p < 0.01, statistical difference observed, using paired, two-tailed t-test.  
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Figure 15. Bortezomib transport and inhibition across MDCK-MDR1 cell at 1, 2, 3 hours 
time points.  
 
The intracellular accumulation increased in the A!C direction after addition of 
GG918 from 3.01 ng to 6.87 ng but didnʼt change in B!C direction (Table 15). 
 
Table 15. Bortezomib intracellular accumulation  
Cell line Condition 
Drug accumulation, ng 
AtoC BtoC 
MDCK-MDR1 
control 3.01±0.28** 5.42±0.31 
w/ 0.5 µM GG918 6.87±1.12** 5.83±0.90 
A, apical side; B, basolateral side; C, intracellular accumulation.  
**p < 0.01, statistical difference observed, using paired, two-tailed t-test 
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12.1.3. Bidirectional transport in Caco-2 cells 
As shown in Table 16 and Figure 16 in Caco-2 cells, apparent permeability in 
direction B!A was greater than A!B in both, control and inhibitory condition. 
Efflux ratio (B!A/ A!B) in control transport buffer was 3.35 and reduced to 1.13 
in presence of GG918 (0.5 μM) (Table 16). According to the results shown in 
Table 5 after inhibition of P-gp there was a significant increase of Papp in the A!B 
direction and decrease in B!A. 
 
Table 16. Bortezomib transport and inhibition across Caco-2 cell monolayer 
Cell line Condition 
Papp, cm/sec x 10-6 
Efflux ratio  
AtoB BtoA 
Caco-2 
control 3.1±0.1**** 10.4±1.0*** 3.35 
w/ 0.5 µM 
GG918 4.61±0.04**** 5.19 ±0.43*** 1.13 
Papp, permeability; A, apical side; B, basolateral side,  
***p < 0.001, statistical difference observed, using paired, two-tailed t-test 
****p < 0.0001, statistical difference observed, using paired, two-tailed t-test 
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Figure 16. Bortezomib transport and inhibition across Caco-2 cell at 1, 2, 3 hours time 
points.  
 
The intracellular accumulation decreased in A!C direction after addition of GG 
918 but didnʼt change in B!C (Table 17). 
 
Table 17. Bortezomib intracellular accumulation  
Cell line Condition 
Drug accumulation, ng 
AtoC BtoC 
Caco-2 
control 10.58±0.21** 3.81±0.45 
w/ 0.5 µM GG918 5.47±1.73** 3.11±1.31 
A, apical side; B, basolateral side; C, intracellular accumulation 
**p < 0.01, statistical difference observed, using paired, two-tailed t-test 
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12.2. Expression of P-gp in multiple myeloma cells after 
treatment with bortezomib 
The viability of U266 cells was significantly affected already at concentrations 
0.0125 µM of bortezomib, leading to an inhibition of 50% after 48 h treatment. 
Protein expression of ABCB1 - In order to determine the effects of long-term 
bortezomib treatment, bortezomib-resistant MM cell line we generated through 
incubation of U266 cells with increasing drug concentrations over a time period of 
four months. Due to the key role of ABCB1 transporter for intracellular bortezomib 
concentrations, we determined ABCB1 protein levels. There was ABCB1 protein 
expression in the U266 cells, under chronic conditions; Caco2 cells, a continuous 
cell line of heterogeneous human epithelial colorectal adenocarcinoma cells, were 
used as positive control, because they express ABCB1 (Figure 17). 
 
 
 
 
 
Figure 17. ABCB1 protein expression in U266 during long-term treatment (Caco2 cells 
were loaded as positive control. The lower bands represent β-actin) 
 
The bidirectional study highlighted the importance of P-gp as bortezomib 
transporter. The western blot study confirm high expression of this efflux 
transporter in multiple myeloma cell line. Additionally, expression of P-gp was 
induced after treatment with bortezomib. The successive pass was to valuate the 
influence of SNPʼs in the gene codifying for P-gp in response to therapy. 
 
 # actin (45kDa) 
µM    0   0.025  0.025 0.0125 0.0125 Caco2 
ABCB1 (170 kDa) 
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12.3. Treatment response according to polymorphisms in ABCB1 
gene. 
In the overall population frequency of the variant ABCB1 allele were as follow: 
0.492 (Hardy-Weinberg P = 0.449) for rs60023214; 0.443 (Hardy-Weinberg P = 
0.642) for rs1128503; 0.422 (Hardy-Weinberg P = 0.631) for rs2038502; 0.423 
(Hardy-Weinberg P = 0.814) for rs10245483; 0.384 (Hardy-Weinberg P = 0.604); 
0.022 (Hardy-Weinberg P = 0.962) for rs3213619. All the studied SNPs were in 
Hardy-Weinberg equilibrium as demonstrated from the reported P value. 
Table 18 shows that there was no correlation between ABCB1 SNPs analysed 
and treatment response. 
Interestingly we found a significant association between ABCB1 variants and 
cytogenetic abnormalities (Table 19). In particular presence of the variants ABCB1 
rs60023214 and rs2038502 are associated with the presence of del(17) (P = 
0.0147 and P = 0.099 respectively) whereas ABCB1 rs2038502 is associated with 
presence of t(4;14) (P = 0.0217). These findings are very interesting. To the best 
of my knowledge is the first time that a genetic SNP is associated with presence of 
genetic abnormalities in MM patients. However, the mechanistic reason for this is 
unknown. 
 
Table 18. Treatment response in the overall population according to 
polymorphisms in ABCB1 gene
 
Genes 
 Overall 
Population 
Poor 
Responders* p value 
RR  
(95% CI) p value 
RR (95% CI) 
Treatment 
adjusted  
ABCB1 
rs60023214 wt 119 58 0.6876  0.9814  
 He 190 86  1 (0.9-1.12)  
1.01 
(0.95-1.06) 
 SNP 114 49  0.95 (0.83-1.09)  
1 
(0.94-1.07) 
ABCB1 
rs1128503 
wt 140 62 0.2537  0.441  
He 193 90  1.09 (0.97-1.21)  
1.04 
(0.97-1.12) 
 SNP 89 40  1 (0.87-1.16)  
1.03 
(0.94-1.12) 
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ABCB1 
rs2038502 wt 138 57 0.5765  0.9183  
 He 215 105  1.03 (0.92-1.16)  
1.01 
(0.96-1.07) 
 SNP 68 30  1.08 (0.94-1.24)  
1.01 
(0.94-1.08) 
ABCB1 
rs10245483 wt 139 61 0.8858  0.99  
 He 214 99  0.98 (0.89-1.09)  
0.95 
(0.84-1.09) 
 SNP 70 33  0.96 (0.83-1.12)  
0.98 
(0.83-1.15) 
ABCB1 
rs3213619 wt 405 184 0.1688  0.1628  
 He 18 9  1.15 (0.99-1.34)  
1.16 
(0.99-1.35) 
 
Table 19. Association between ABCB1 variants and cytogenetic abnormalities.
 
Genes 
 Overall 
pop.* 
Del(17) 
Yes 
P 
value 
RR 
(95% CI) 
Overall 
pop.* 
T(4;14) 
Yes 
P 
value 
RR 
(95% CI)  
ABCB1 
rs60023214 wt 119 4 0.0147  126 31 0.1805  
 He 190 21  3.29 (1.16-9.34) 205 36  
0.71 
 (0.47-1.09) 
 SNP 114 5  1.3 (0.36-4.74) 119 19  
0.65 
 (0.39-1.08) 
ABCB1 
rs1128503 wt 140 6 0.2448  146 33 0.4359  
 He 193 17  2.06 (0.83-5.08) 209 36  
0.76 
( 0.5-1.16) 
 SNP 89 7  1.84 (0.64-5.28) 94 17  
0.8 
(0.47-1.35) 
ABCB1 
rs2038502 wt 138 4 0.0099  144 38 0.0217  
 He 215 23  3.69 (1.3-10.4) 230 39  
0.64 
(0.43-0.95) 
 SNP 68 3  1.52 (0.35-6.61) 73 9  
0.47 
(0.24-0.91) 
ABCB1 
rs10245483 wt 139 8 0.7302  147 25 0.5409  
 He 214 17  1.38 (0.61-3.11) 227 48  
1.24 
( 0.8-1.92) 
 SNP 70 5  1.24 (0.42-3.65) 76 13  
1.01 
(0.55-1.85) 
ABCB1 
rs3213619 wt 405 29 0.7882  430 82 0.9181  
 He 18 1  0.78 (0.11-5.38) 20 4  
1.05 
(0.43-2.57) 
 
* Overall pop. = Overal population 
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Conclusions 
The principle aim of this study was to investigate some of the possible 
biological predictors of response and resistance to multiple myeloma treatment 
with bortezomib as well as prognostic factors for therapeutic outcome 
independently from the regimen. Inter-individual variability is one of the cause of 
differences in response to bortezomib therefore the study had mainly the 
pharmacogenetic approach. 
At first, the resistance to MM treatment with bortezomib was approached from 
a strictly pharmacodynamic point of view. One of the proposed mechanisms of 
action of bortezomib as well as common resistance mechanism to cancer 
treatment is directly depending on DNA repair system. This linkage was a trigger 
to hypotheses that poor response to MM treatment may be correlated with inter-
individual differences in genes coding for main proteins in DNA repair system and 
folic acid metabolism pathway which directly supports DNA repair system [126]. 
Our analysis identified two SNPs in folic acid metabolism pathway, which might be 
very important for the future understanding of multiple myeloma disease as well as 
its treatment. MTR gene was associated with favourable response in the overall 
population of MM patients. However, this relation, disappear after adjustment for 
treatment response. 
MTFHR rs1801131 genotype was associated with poor response to therapy 
induction in newly diagnosed MM patients. This relation - unlike in MTR – was still 
significant after adjustment for treatment response. Identification of this genetic 
variant in MM patients could be used as an independent prognostic factor for 
therapeutic outcome in the clinical practice. 
Secondly, P-gp was hypnotized as a factor of resistance on the 
pharmacokinetic and pharmacodynamic level. P-gp is well known efflux 
transporter affecting disposition of small molecules in the whole body as well as 
their concentration in the site of action. Itʼs capacity to eliminate xenobiotics from 
cancer cells and from eliminating organs, as liver, is well known cause of therapy 
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failure. Bi-directional transport study clearly demonstrated high efflux activity of P-
gp on bortezomib what directed investigation to pharmacogenetics of this 
transporter.  
Permeability rate values measured for bortezomib in bi-directional transport study 
together with solubility values found in the literature let possible classification of 
bortezomib in Biopharmaceutics Classification System as a Class III drug [127]. 
This discover can have a crucial implication in better understanding of 
bortezomibʼs pharmacokinetics with respect to the importance of membrane 
transporters as well as in the future preparation of oral formulation of this drug.  
To investigate pharmacodynamic implications of bortezomib interaction with P-gp, 
significant up-regulation of this glicoproteine after bortezomib treatment was 
confirmed by western blot analysis. Successively most frequent SNPs in ABCB1 
(gene coding for P-gp) were correlated with MM treatment response as well as 
cytogenetic abnormalities. 
None of the Five SNPs in ABCB1 correlated with treatment responsiveness, 
although we found a significant association between these variants and 
cytogenetic abnormalities. In particular, deletion of chromosome 17 and t(4;14) 
translocation were significantly present in harboring the rs60023214 and 
rs2038502 variants respectively. This new linkage between genetic make-up in the 
healthy somatic cells with chromosome abnormality in MM cancer cells may open 
an interesting discussion about hereditary characteristic of this disease. 
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